Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. by Fletcher, Helen A et al.
Harris, SA; Meyer, J; Satti, I; Marsay, L; Poulton, ID; Tanner, R;
Minassian, AM; Fletcher, HA; McShane, H (2013) Evaluation of a
human BCG challenge model to assess anti-mycobacterial immunity
induced by BCG and a candidate TB vaccine, MVA85A, alone and
in combination. The Journal of infectious diseases. ISSN 0022-1899
Downloaded from: http://researchonline.lshtm.ac.uk/1367749/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
M A J O R A R T I C L E
Evaluation of a Human BCG Challenge Model to
Assess Antimycobacterial Immunity Induced by
BCG and a Candidate Tuberculosis Vaccine,
MVA85A, Alone and in Combination
Stephanie A. Harris,a Joel Meyer,a Iman Satti, Leanne Marsay, Ian D. Poulton, Rachel Tanner, Angela M. Minassian,
Helen A. Fletcher, and Helen McShane
Jenner Institute, University of Oxford, Oxford, United Kingdom
Background. A new vaccine is urgently needed to combat tuberculosis. However, without a correlate of protection,
selection of the vaccines to take forward into large-scale efﬁcacy trials is difﬁcult. Use of bacille Calmette-Guérin (BCG)
as a surrogate for humanMycobacterium tuberculosis challenge is a novel model that could aid selection.
Methods. Healthy adults were assigned to groups A and B (BCG-naive) or groups C and D (BCG-vaccinated).
Groups B and D received candidate tuberculosis vaccine MVA85A. Participants were challenged with intradermal BCG
4 weeks after those who received MVA85A. Skin biopsies of the challenge site were taken 2 weeks post challenge and
BCG load quantiﬁed by culture and quantitative polymerase chain reaction (qPCR).
Results. Volunteers with a history of BCG showed some degree of protective immunity to challenge, having lower
BCG loads compared with volunteers without prior BCG, regardless of MVA85A status. There was a signiﬁcant inverse
correlation between antimycobacterial immunity at peak response after MVA85A and BCG load detected by qPCR.
Conclusion. Our results support previous ﬁndings that this BCG challenge model is able to detect differences
in antimycobacterial immunity induced by vaccination and could aid in the selection of candidate tuberculosis vaccines
for ﬁeld efﬁcacy testing.
Clinical Trials Registration. NCT01194180.
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Disease caused by Mycobacterium tuberculosis contin-
ues to be a major global health problem. In 2011, 8.7
million new cases of tuberculosis were diagnosed
worldwide and 1.4 million people died from the disease
[1].With tuberculosis causing a quarter of the deaths in
people living with human immunodeﬁciency virus
(HIV) [1] and with the emergence of increasingly
drug-resistant strains of M. tuberculosis, an effective
vaccine is urgently needed now in order to reduce the
burden of this disease.
Since 2002, more than a dozen candidate vaccines
have been entered into clinical testing [2]. However, it
is difﬁcult to determine which of these candidates will
progress from relatively small-scale safety and immu-
nogenicity studies through to large-scale, expensive
efﬁcacy trials because an immune correlate of vaccine-
induced protection against infection or disease does
not exist. Preclinical animal challenge models of M. tu-
berculosis infection [3–6] and in vitro mycobacterial
killing assays [7–9] are used to assess vaccine efﬁcacy.
However, it is not clear whether either of these reliably
predict what occurs in vivo in humans. Thus, the evalu-
ation of vaccine efﬁcacy currently relies on large,
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expensive, and time-consuming efﬁcacy trials. A human myco-
bacterial challenge model that could be used to assess the efﬁca-
cy of candidate tuberculosis vaccines at an early stage would
be a great advancement to the ﬁeld. Human challenge models
are routinely used in vaccine development for pathogens such
as malaria, inﬂuenza, dengue fever, and typhoid [10–13]; how-
ever, the deliberate infection of humans with M. tuberculosis
would not be ethically acceptable. Previously, we demonstrated
that a novel human challenge model that uses bacille Calmette-
Guérin (BCG) as a surrogate for M. tuberculosis infection can
detect differences in antimycobacterial immunity induced by
previous BCG vaccination [14]. In this earlier trial, healthy vol-
unteers were challenged with intradermal BCG. The BCG load
was then quantiﬁed from a skin biopsy at the challenge site at 1,
2, and 4 weeks post challenge by culture on solid agar and
quantitative polymerase chain reaction (qPCR). It was found
that optimum recovery of BCG was achieved in 2 weeks; this
time period was chosen for future challenge studies. Here we
use this BCG challenge model to evaluate the reduction in my-
cobacterial load induced by BCG alone; a candidate tuberculo-
sis vaccine, MVA85A; and a BCG prime–MVA85A boost
vaccine regimen.
METHODS
Trial Design
This phase 1 trial (ClinicalTrial.gov registry NCT01194180)
was approved by the Medicines and Healthcare Products
Regulatory Agency (EudraCT 2010-018425-19) and the Ox-
fordshire Research Ethics Committee A (reference 10/H0505/
31). Twenty-six BCG-vaccinated and 23 BCG-naive healthy
volunteers aged 18–55 years were enrolled between March 2011
and November 2011 at the Centre for Clinical Vaccinology &
Tropical Medicine, Churchill Hospital, Oxford, United King-
dom (see Figure 1). All participants gave written informed con-
sent, and the trial was conducted according to the principles of
the Declaration of Helsinki and Good Clinical Practice.
Those enrolled were in good health, had normal baseline
hematology and biochemistry, and were serologically negative
for hepatitis B, hepatitis C, and HIV. Latent infection with
M. tuberculosis was excluded by a negative ex vivo enzyme-
linked immunosorbent spot (ELISpot) assay response to
ESAT-6 and CFP-10 peptides. The reasons for exclusion of 9
participants are shown in Figure 1. One individual in group B
had to withdraw from follow-up for personal reasons after
Figure 1. Consort diagram showing participant recruitment and follow-up. *One volunteer withdrew from group B for personal reasons after MVA85A
vaccination but before bacille Calmette-Guérin challenge.
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receiving MVA85A but before BCG challenge and was therefore
replaced.
Treatment Groups
Participants were assigned to group A (BCG-naive; no vaccine
received), group B (BCG-naive at baseline; received intradermal
MVA85A, dose 1 × 108 pfu), group C (BCG-vaccinated at base-
line; median time since vaccination 10 years), or group D
(BCG-vaccinated at baseline; median time since vaccination
10.5 years; received intradermal MVA85A, dose 1 × 108 pfu)
based on their prior BCG vaccination status and meeting inclu-
sion criteria. One volunteer who was enrolled into group A on
the basis of negative BCG status was later reassigned to group C
after discovering that he/she had, in fact, received BCG as an
infant (Figure 1).
Vaccine
Clinical-grade MVA85A was constructed as previously de-
scribed [15] and produced following good manufacturing prac-
tices by IDT Biologika GmbH (Dessau-Rosslau, Germany).
Challenge
All participants were challenged with a standard vaccine dose
of intradermal BCG (SSI (Statens Serum Institut); 0.1 mL
containing 2 to 8 × 105 CFU). Those in groups B and D were
challenged 4 weeks after MVA85A vaccination. To minimize
variation between BCG vials, as many volunteers as possible
were challenged from the same vial of BCG within 2 hours of
reconstitution (15 different BCG vaccine vials were used over
the course of the trial to challenge 48 volunteers). The chal-
lenge dose was veriﬁed by plating serial dilutions of a 100-µL
aliquot onto solid Middlebrook 7H10 agar (Sigma).
Skin Biopsies
Skin biopsies were performed on the BCG challenge site of all
48 volunteers by a single operator 2 weeks post challenge as
previously described [14]. The 4-mm punch biopsy specimen
was taken from the center of the BCG vaccination site, trans-
ferred to a sterile Cryovial, snap frozen on dry ice, and stored in
liquid nitrogen until the day of processing.
Biopsy Homogenization and Culture
All 48 biopsies were processed on the same day. Samples were
thawed in a 37°C water bath and transferred to a Dispomix
tube (Miltenyl Biotech) that contained 1 mL sterile phosphate-
buffered saline (PBS). Tubes were loaded onto a Dispomix
machine (Thistle Scientiﬁc) and homogenized as previously de-
scribed [16]. Next, 100 µL of neat homogenate and 100 µL of a
10−1 and 10−2 dilution were plated in triplicate onto Middle-
brook 7H10 agar and incubated at 37°C for 5 weeks. A BCG
SSI vaccine vial was reconstituted in PBS and 100 µL of a 10−2,
10−3, and 10−4 dilution were plated in triplicate as positive
controls. The remaining biopsy homogenate was stored at −20°C
for later DNA extraction.
DNA Extraction
Homogenate was thawed and BCG DNA from 200 µL homoge-
nate was released using the tough microorganism lysing kit
(Precellys) in a Precellys 24 machine at 6500 rpm for 3 × 30
seconds. Homogenate was transferred to a separate tube, and
50 µL PBS was used to wash the remaining homogenate from
the beads. Next, 180 µL animal tissue lysis buffer and 20 µL
proteinase K (Qiagen) were added, vortexed, and incubated at
56°C for 4 hours. From this point, the extractions were carried
out as previously described [16].
qPCR
Primers ET 1 and ET 3 were used for detection of BCG DNA.
These are complementary to regions that ﬂank the BCG dele-
tion RD1 sequence and amplify a 196-bp fragment [17]. These
sequences were modiﬁed by Minassian et al [16], and the modi-
ﬁed sequences were used for this work (Table 1). PCR reactions
were carried out as previously described [16] using BCG-naive
macaque tissue homogenate as a negative control. A standard
curve was obtained by extracting BCG DNA from 1 in 10 serial
dilutions of 5 pooled vaccine vials in PBS and correcting for
live BCG from the corresponding colony-forming unit counts
on solid agar.
Ex vivo Interferon-gamma ELISpot Assay
Peripheral blood mononuclear cells (PBMCs) were isolated
from whole blood and ELISpots were performed as previously
described [18]. This occurred for all volunteers on the day of
screening, the day of BCG challenge, and the day of skin
biopsy. Groups B and D also had an ELISpot performed 7 days
after MVA85A vaccination, which occurred 21 days prechal-
lenge. Responses to puriﬁed protein derivative (PPD) from
M. tuberculosis (SSI; 20 µg/mL) and a single pool of 66 Ag85A
peptides (Peptide Protein Research; 2 µg/mL each peptide)
were assessed for all volunteers at each time point. Staphylo-
coccal enterotoxin B (Sigma) was used as a positive control
(10 µg/mL). Unstimulated PBMCs were used as a measure of
background interferon-gamma (IFN-γ) production. Results are
reported as spot-forming cells (SFC) per million PBMC, cal-
culated by subtracting the mean count of the unstimulated
PBMCs from the mean count of duplicate antigen wells and
correcting for the number of PBMCs in the well.
Table 1. Primer Sequences Used to Detect Bacille Calmette-
Guérin by Quantitative Polymerase Chain Reaction
Primer Primer Sequence
ET 1/3 forward 5′ -CCG CCG ACC GAC CTG ACG AC- 3′
ET 1/3 reverse 5′ -GGC GAT CTG GCG GTT TGG GG- 3′
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Whole Blood Growth Inhibition Assay
The whole blood growth inhibition assay was performed on
heparinized whole blood on the day of BCG challenge using
the BACTEC mycobacteria growth indicator tube (MGIT)
system (Becton Dickinson) as previously described [19], with
the exception that whole blood was incubated with BCG
(Pasteur) for 96 hours instead of 72 hours. Growth inhibition
was determined by calculating time to positivity (TTP) in the sam-
ple and TTP in the control and converting to colony-forming
units using a standard curve. The growth ratio (GR) was calculat-
ed by GR =CFU sample (96 hours)/CFU control (0 hours).
Swabbing of BCG Vaccination Site
The feasibility of swab-based quantiﬁcation of BCG from the
surface of the BCG challenge vaccination site, as an alternative
or complementary technique to the biopsy technique, was in-
vestigated in a separate cohort of healthy volunteers (study
approved by the University of Oxford Central University Re-
search Ethics Committee, reference MSD/IDREC/C1/2012/7).
Seven BCG-naive, adult healthcare workers who were due to
receive BCG vaccination for employment reasons were recruit-
ed and gave written informed consent. Cotton-tipped swabs
(Transwab MW171, Medical Wire & Equipment) were used to
swab the surface of the BCG site at 2, 7, 14, and 21 days follow-
ing vaccination. The ability of this method to recover BCG
from the swabs was tested before the study began. Serial dilu-
tions of a BCG vaccine vial (SSI) were made and 100 µL of each
dilution was plated onto Middlebrook 7H10 agar. Twenty mi-
croliters of each dilution was used to spike the swabs, which
were then immersed in 500 µL Middlebrook 7H9 broth
(Sigma), left for 1 hour, and sonicated for 30 seconds. 300 µL
of broth was then plated onto Middlebrook 7H10 agar and in-
cubated at 37°C for 3 weeks. The number of colonies recovered
was compared with the inoculum in 20 µL. Swabs from the
BCG vaccination site were processed in the same way.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism.
One-way analysis of variance (Kruskal-Wallis) and Mann–
Whitney U tests were used to determine signiﬁcant differences
between groups. The Wilcoxon matched pairs test was used to
determine differences between time points in the same group.
The Spearman rank correlation test was used to determine cor-
relations between numbers of BCG recovered from biopsies
and ex vivo IFN-γ ELISpot responses.
RESULTS
BCG Challenge Was Safe and Well Tolerated by All Groups
Other than BCG vaccination status, the volunteers’ baseline
characteristics did not signiﬁcantly differ among the 4 groups
(Table 2). BCG challenge was well tolerated, with all volunteers
developing an expected local inﬂammatory reaction to BCG. It
was noted that previously BCG-vaccinated volunteers (groups
C and D) experienced signiﬁcantly more frequent local adverse
events and signiﬁcantly greater diameters of erythema and
swelling at the challenge vaccination site during the ﬁrst 2
weeks than did BCG-naive volunteers (groups A and B; data
not shown), which is consistent with previous studies [20, 21].
Intradermal administration of candidate vaccine MVA85A at a
dose of 1 × 108 pfu was safe and well tolerated, with an adverse
event proﬁle consistent with previous experience [18, 22]. No
serious adverse events occurred. Vaccination with MVA85A 4
weeks before challenge had no effect on the reactogenicity of
the subsequent BCG challenge.
BCG Was Detected by Both qPCR and Culture
BCG was detected in all 48 biopsy samples by qPCR and in 45
of 48 samples by culture on solid agar (Figure 2). Estimated
copy numbers per biopsy using PCR were 1–2 logs higher than
the corresponding colony-forming unit counts by culture. A
Table 2. Demographics of Enrolled Participants
Characteristic Group A (n = 11) Group B (n = 12) Group C (n = 13) Group D (n = 12) P Value
Prior BCG No No Yes Yes
MVA85A No Yes No Yes
Female, n (%) 8 (73) 7 (58) 6 (46) 6 (50) 0.58
Median age, years (range) 23 (18–41) 23 (19–30) 23 (21–41) 22 (19–33) 0.63
Median time interval since BCG in years (range) n/a n/a 10 (8–38) 10.5 (6–33) 0.48
Continent of birth
Europe 9 8 13 10
Africa 0 0 0 1
Asia 0 0 0 1
Americas 1 3 0 0
Australasia 1 1 0 0
Abbreviations: BCG, bacille Calmette-Guérin; n/a, not applicable.
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positive correlation was observed between the 2 methods of
detection (Spearman R = 0.36, P = .01; Figure 2).
BCG Challenge Dose Administered Was Comparable for All
Volunteers
Quantiﬁcation of BCG from each vaccine vial used in this trial
showed that the range in challenge dose was small (1.85 × 105
to 3.15 × 105 cfu, median = 2.35 × 105 cfu) and at the lower end
of that stated by the manufacturer [23].
Levels of BCG Recovered Were Lower in Groups With Previous
BCG Vaccination
Enumeration of BCG by solid culture showed a trend toward a
lower median colony-forming unit count in the previously
BCG-vaccinated groups, with a statistically signiﬁcant 0.5-log
reduction in colony-forming unit count between group A
(naive) and group D (BCG–MVA85A; P = .02, Mann–Whitney
U test; Figure 2). Using PCR, there was a signiﬁcant 0.5- to 1-
log reduction in estimated BCG copy number between the
BCG-naive (A or B) and BCG-vaccinated groups (C or D;
Mann–Whitney U test). No further reduction in BCG numbers
was detected after vaccination with MVA85A.
Ex Vivo IFN-γ ELISpot Responses Were as Expected for
Vaccination Schedule Received
Ex vivo IFN-γ ELISpot responses to PPD and a single pool of
Ag85A peptides are shown in Figure 3. There were no signiﬁ-
cant differences in baseline Ag85A responses among the 4
groups (data not shown for groups A and C); however, baseline
PPD responses were signiﬁcantly higher (P = .008, Mann–
Whitney U test) in the previously BCG-vaccinated groups.
Those in group D who received MVA85A as a boost to BCG
had signiﬁcantly higher responses to Ag85A 7 days post vacci-
nation than those in group B who were BCG naive, as
Figure 2. Quantiﬁcation of bacterial load from punch biopsies 14 days post bacille Calmette-Guérin (BCG) challenge by culture on solid agar (A) and
quantitative polymerase chain reaction (qPCR) (B). Individual values are shown for each volunteer. Horizontal bars indicate median values in each group.
Signiﬁcant differences between groups are as follows: *P≤ .05, **P≤ .01, ***P≤ .001; Mann–Whitney U test. A signiﬁcant positive correlation was ob-
served between the culture and qPCR results (C).
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Figure 3. Ex vivo interferon-gamma enzyme-linked immunosorbent spot (ELISpot) assay responses to puriﬁed protein derivative from Mycobacterium
tuberculosis for all groups (A) and to a single pool of Ag85A peptides for groups B and D (B). A value of 1667 spot-forming cells (SFCs)/1 × 106 peripheral
blood mononuclear cells (PBMCs) represents a blackout in the ELISpot well. ** P < .01. Abbreviation: BCG, bacille Calmette-Guérin.
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previously reported [24]. However, Ag85A responses between
the 2 groups were not signiﬁcantly different on the day of chal-
lenge or on the day of biopsy. Responses to PPD on the day of
challenge were signiﬁcantly lower in group A compared with
each of the other 3 groups; however, there was no signiﬁcant
difference in responses among groups B, C, and D at this time
point. PPD responses for those in groups A and C were signiﬁ-
cantly higher 14 days post challenge than for those measured
on the day of challenge (P = .002 and .0002, respectively; Wil-
coxon matched-pairs). This signiﬁcant increase was not ob-
served in groups B and D due to the confounding effect of
recent vaccination with MVA85A.
Ex Vivo IFN-γ ELISpot Responses Correlate With Number of
BCG Detected
The correlation between ex vivo IFN-γ ELISpot responses and
BCG colony number detected by PCR is shown in Figure 4. An
inverse correlation was observed at all time points for responses
to PPD and Ag85A, and this correlation is signiﬁcant for both
antigens 7 days after receipt of MVA85A (P = .005, Spearman)
and for PPD 14 days post challenge (P = <.0001, Spearman).
The same trend was observed when ELISpot responses were
correlated with colony-forming unit counts by culture but did
not reach statistical signiﬁcance at any time point (data not
shown).
In Vitro Mycobacterial Growth Inhibition Did Not Differ Among
Groups on Day of Challenge
Figure 5 shows the growth ratios obtained from incubating
whole blood taken on the day of challenge with BCG in the
MGIT assay. This assay detected no signiﬁcant differences
among the 4 treatment groups in the ability of whole blood to
reduce growth of BCG during a 96-hour incubation period
(P = .13, Kruskal-Wallis). A nonsigniﬁcant positive correlation
was observed between growth ratio and BCG copy number by
PCR (Figure 5B) and also between growth ratio and colony-
forming unit count (data not shown).
BCG Was Not Detected From Swabbing of the BCG Vaccination
Site
BCG could not be detected by swabbing of the vaccination site
in any of the volunteers at any of the time points investigated,
by either culture on solid agar or qPCR. This is despite an
average recovery of 88% by culture when swabs were spiked
with serial dilutions of a BCG vaccine vial.
DISCUSSION
Here we present a proof-of-concept clinical trial to evalu-
ate a novel BCG challenge model in BCG- and/or MVA85A-
vaccinated adults.
In this trial, 48 volunteers were challenged with a standard
vaccine dose of BCG. A punch biopsy of the vaccination site
was taken 14 days later. BCG was detected in all 48 biopsies by
qPCR and in 45 of 48 biopsies by culture on solid agar. It has
been shown that estimated copy numbers using PCR were 1–2
logs higher than the corresponding colony-forming unit counts
[14], even though a positive correlation was observed between
the 2 methods of detection. The discrepancy between the 2
methods of quantiﬁcation is most likely due to the fact that
PCR does not distinguish between live and dead BCG, whereas
culture only detects viable bacteria. The challenge dose received
by each volunteer was similar and no correlation was observed
between challenge dose and BCG recovery. BCG could not be
detected by either culture or qPCR after swabbing of the BCG
vaccination site in a separate cohort.
A signiﬁcant reduction in BCG was detected by solid culture
in the BCG–MVA85A group compared with the naive group.
Using PCR, there was a signiﬁcant 0.5- to 1-log reduction in
BCG copy number in the 2 groups that had been BCG vaccinat-
ed when compared with the 2 BCG-naive groups. These ﬁnd-
ings suggest that prior BCG vaccination gives some protection
against a subsequent challenge dose. Administration of
MVA85A 4 weeks prior to BCG challenge had no added effect
on the reduction of numbers of BCG detected. This ﬁnding is
consistent with data recently published on the efﬁcacy of
MVA85A in a phase 2b trial in BCG-vaccinated infants in
South Africa where boosting with MVA85A conferred no sig-
niﬁcant efﬁcacy over BCG alone [25].
Vaccination with MVA85A induced a range of ex vivo IFN-γ
ELISpot responses to Ag85A 7 days post vaccination (83–1667
sfc/million PBMC, median 1649), which inversely correlated
with the number of colony-forming units recovered from the
punch biopsies. The same inverse correlation was observed
with PPD responses from PBMC isolated 14 days post chal-
lenge, suggesting that IFN- γ produced from antigen-speciﬁc
CD4+ effector T cells is important for bacterial clearance from
the challenge site.
The MGIT assay did not detect any differences between the
groups’ ability to reduce growth of BCG when incubated with
whole blood on the day of challenge. The lack of detectable diffe-
rence between the BCG-naive and BCG-vaccinated groups may
be due to the length of time between BCG vaccination and when
the MGIT assay was performed, that is, a median of 10 and 10.5
years for groups C and D, respectively. Other in vitro studies
have shown enhanced mycobacterial growth inhibition due to
BCG vaccination involving shorter time intervals (2–12 months)
between vaccination and performance of the assays [26–29].
Comparison of this human BCG challenge model to animal
M. tuberculosis challenge models shows a comparable effect of
prior BCG vaccination. The same is not true of MVA85A,
which has been shown to improve efﬁcacy over BCG alone
when given as a boost in preclinical animal models [5, 6, 30,
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31]. However, in the animal challenge models, a high dose of
M. tuberculosis is given by the aerosol route, while a standard
vaccine dose of BCG is given by the intradermal route in the
human model. Therefore, the challenge dose of BCG may be
too low to detect further improvement over BCG alone. Further
data are needed to truly compare the 2 models.
Figure 4. Correlation between ex vivo interferon-gamma enzyme-linked immunosorbent spot assay responses to puriﬁed protein derivative or Ag85A
and estimated bacille Calmette-Guérin (BCG) copy number by polymerase chain reaction (PCR). Spearman R values are shown with asterisks indicating
P values as follows: *P≤ .05, **P≤ .01, ***P≤ .001. Abbreviations: PBMC, peripheral blood mononuclear cell; SFC, spot-forming cell.
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Data from this study support previous ﬁndings that this
novel BCG challenge model can detect differences in antimy-
cobacterial immunity induced by vaccination. In this trial, a
difference could be detected between prior BCG vaccination
and no prior BCG vaccination. MVA85A vaccination 4 weeks
before challenge did not appear to further inhibit BCG
growth. However, this study was performed in a population
in which BCG had been demonstrated to be extremely effec-
tive [32]. Therefore, it might not be possible to see a addi-
tional effect of MVA85A vaccination with such small group
sizes and numbers of BCG recovered. Model sensitivity needs
to be improved, and further challenge trials are planned to
address this issue. This will be done by varying the BCG
challenge strain and the dose. The optimum time interval
between vaccination and challenge also needs to be consid-
ered. After these parameters have been optimized, the study
must be repeated with larger groups. The model also merits
evaluation in populations where the BCG vaccine has a lower
efﬁcacy. Also, further work is needed to determine the target
population and type of vaccine candidate that this BCG chal-
lenge model has utility for.
In the absence of a correlate of protection against M. tuber-
culosis, human BCG challenge provides a useful model to
complement preclinical animal testing and immunological as-
sessment to allow optimal selection of vaccines that will pro-
gress to ﬁeld efﬁcacy testing.
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